Literature DB >> 18383211

Cells expressing partially unfolded R789C/p.R989C type II procollagen mutant associated with spondyloepiphyseal dysplasia undergo apoptosis.

Vera Hintze1, Andrzej Steplewski, Hidetoshi Ito, Deborah A Jensen, Ulrich Rodeck, Andrzej Fertala.   

Abstract

We investigated the effects of the presence of R75C (p.R275C), R519C (p.719C), R789C (p.R989C), and G853E (p.G1053E) type II collagen (COL2A1) mutants, associated with distinct forms of spondyloepiphyseal dysplasia (SED), on the biological processes occurring in chondrocytic cells harboring those mutants. Mutant-specific biological responses of cells were initiated by activating tetracycline (Tet)-dependent expression of type II collagen mutants. Employing microscopic and biochemical assays, we determined that cells expressing the thermolabile R789C (p.R989C) type II collagen mutant undergo apoptosis. In contrast, in cells expressing the thermostable R75C (p.R275C), R519C (p.719C), and G853E (p.G1053E) mutants, apoptotic markers were not apparent. We also demonstrated that the R789C (p.R989C) mutant formed atypical complexes with endoplasmic reticulum (ER)-resident chaperones, thereby indicating an "unfolded protein response" (UPR) of cells harboring this specific mutant. Apoptotic changes were also demonstrated by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and cleaved caspase 3 assays in the growth plates of mice harboring the R992C (p.R1147C) substitution in type II collagen. Based on these results, we propose that the intracellular presence of structurally altered type II collagen mutants could activate an apoptotic response, thereby limiting cell survival. By analyzing the response of cells to the altered structure of collagen mutants, our study contributes to better understanding the molecular basis of the pathological changes seen in vivo at the tissue level. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383211     DOI: 10.1002/humu.20736

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

1.  The expanding spectrum of COL2A1 gene variants IN 136 patients with a skeletal dysplasia phenotype.

Authors:  Mouna Barat-Houari; Bruno Dumont; Aurélie Fabre; Frédéric Tm Them; Yves Alembik; Jean-Luc Alessandri; Jeanne Amiel; Séverine Audebert; Clarisse Baumann-Morel; Patricia Blanchet; Eric Bieth; Marie Brechard; Tiffany Busa; Patrick Calvas; Yline Capri; François Cartault; Nicolas Chassaing; Vidrica Ciorca; Christine Coubes; Albert David; Anne-Lise Delezoide; Delphine Dupin-Deguine; Salima El Chehadeh; Laurence Faivre; Fabienne Giuliano; Alice Goldenberg; Bertrand Isidor; Marie-Line Jacquemont; Sophie Julia; Josseline Kaplan; Didier Lacombe; Marine Lebrun; Sandrine Marlin; Dominique Martin-Coignard; Jelena Martinovic; Alice Masurel; Judith Melki; Monique Mozelle-Nivoix; Karine Nguyen; Sylvie Odent; Nicole Philip; Lucile Pinson; Ghislaine Plessis; Chloé Quélin; Elise Shaeffer; Sabine Sigaudy; Christel Thauvin; Marianne Till; Renaud Touraine; Jacqueline Vigneron; Geneviève Baujat; Valérie Cormier-Daire; Martine Le Merrer; David Geneviève; Isabelle Touitou
Journal:  Eur J Hum Genet       Date:  2015-12-02       Impact factor: 4.246

2.  An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis.

Authors:  Albert S Jun; Huan Meng; Naren Ramanan; Mario Matthaei; Shukti Chakravarti; Richard Bonshek; Graeme C M Black; Rhonda Grebe; Martha Kimos
Journal:  Hum Mol Genet       Date:  2011-10-14       Impact factor: 6.150

Review 3.  Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.

Authors:  John F Bateman; Raymond P Boot-Handford; Shireen R Lamandé
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

4.  Matrix-specific anchors: a new concept for targeted delivery and retention of therapeutic cells.

Authors:  Andrzej Steplewski; Jolanta Fertala; Pedro Beredjiklian; Mark L Wang; Andrzej Fertala
Journal:  Tissue Eng Part A       Date:  2015-01-13       Impact factor: 3.845

5.  Reducing the effects of intracellular accumulation of thermolabile collagen II mutants by increasing their thermostability in cell culture conditions.

Authors:  Katarzyna Gawron; Deborah A Jensen; Andrzej Steplewski; Andrzej Fertala
Journal:  Biochem Biophys Res Commun       Date:  2010-04-13       Impact factor: 3.575

6.  ENU-induced missense mutation in the C-propeptide coding region of Col2a1 creates a mouse model of platyspondylic lethal skeletal dysplasia, Torrance type.

Authors:  Tatsuya Furuichi; Hiroshi Masuya; Tomohiko Murakami; Keiichiro Nishida; Gen Nishimura; Tomohiro Suzuki; Kazunori Imaizumi; Takashi Kudo; Kiyoshi Ohkawa; Shigeharu Wakana; Shiro Ikegawa
Journal:  Mamm Genome       Date:  2011-05-03       Impact factor: 2.957

7.  Persistence of intracellular and extracellular changes after incompletely suppressing expression of the R789C (p.R989C) and R992C (p.R1192C) collagen II mutants.

Authors:  Deborah A Jensen; Andrzej Steplewski; Katarzyna Gawron; Andrzej Fertala
Journal:  Hum Mutat       Date:  2011-05-05       Impact factor: 4.878

8.  Remodeling of the dermal-epidermal junction in bilayered skin constructs after silencing the expression of the p.R2622Q and p.G2623C collagen VII mutants.

Authors:  Andrzej Steplewski; Anthony Kasinskas; Andrzej Fertala
Journal:  Connect Tissue Res       Date:  2012-04-10       Impact factor: 3.417

9.  Fluorescent protein markers to tag collagenous proteins: the paradigm of procollagen VII.

Authors:  Hye Jin Chung; Andrzej Steplewski; Jouni Uitto; Andrzej Fertala
Journal:  Biochem Biophys Res Commun       Date:  2009-10-12       Impact factor: 3.575

10.  R992C (p.R1192C) Substitution in collagen II alters the structure of mutant molecules and induces the unfolded protein response.

Authors:  Hye Jin Chung; Deborah A Jensen; Katarzyna Gawron; Andrzej Steplewski; Andrzej Fertala
Journal:  J Mol Biol       Date:  2009-05-08       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.